



Low *In Vitro* Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis

Mahdi Abastabar,^a Iman Haghani,^a  Tahereh Shokohi,^a  Mohammad Taghi Hedayati,^a Seyed Reza Aghili,^a Ali Jedi,^b Sulmaz Dadashi,^b Shafiqeh Shabanzadeh,^a Tahereh Hosseini,^b Narges Aslani,^c  Jacques F. Meis,^{d,e}  Hamid Badali^{a,f}

^aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

^bStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran

^cDepartment of Medical Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran

^dCentre of Expertise in Mycology Radboud University Medical Centre/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

^eDepartment of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

^fDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

ABSTRACT The *in vitro* activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to *Candida* species, *Aspergillus* species, and dermatophytes.

KEYWORDS tavaborole, antifungal, onychomycosis

Fungal nail infections are common and recurrent problems caused predominantly by different species of dermatophytes, *Candida*, and filamentous fungi. The distribution pattern has been reported to be variable in different geographic regions (1–3). Whereas most reports indicate that *Trichophyton rubrum* and *Trichophyton interdigitale* are the most common agents of onychomycosis, several fungal genera, such as *Candida*, *Aspergillus*, *Fusarium*, *Scopulariopsis*, *Acremonium*, *Onychocola*, and *Penicillium*, have been isolated from nail samples (4–9). Estimates of the prevalence rate of onychomycosis in the different communities range from 0.5% to 30% (6, 10, 11). It may affect patients with advanced age, distorted nails, hyperhidrosis, diabetes, psoriasis, peripheral vascular disease, genetic predisposition, and immunosuppression (8, 9). Currently, the preferred treatments for onychomycosis include itraconazole, terbinafine, and fluconazole combined with topical nail formulations, such as luliconazole 1% (12, 13), efinaconazole 10% (14), amorolfine 5%, and ciclopirox 8% (15). Despite the introduction of new generations of antimycotics, as well as laser and photodynamic therapy, achievement of complete cure is challenging (16, 17). Tavaborole (5%), a boronic acid quinolone compound, received FDA approval in 2014 for use in the topical treatment of onychomycosis (17). This drug has a unique mechanism of inhibition among antifungals, targeting the leucyl-tRNA synthetase enzyme and thus preventing protein synthesis (18, 19). Tavaborole, due to its small molecular weight, demonstrated appropriate safety with excellent nail penetration through keratin layers (20). Previous limited studies using a few strains showed that tavaborole had *in vitro* activity against *Trichophyton*, *Candida*, *Aspergillus*, and *Fusarium* (21, 22), although no antifungal susceptibility data of tavaborole against a large

Received 1 August 2018 Returned for modification 25 August 2018 Accepted 5 September 2018

Accepted manuscript posted online 17 September 2018

Citation Abastabar M, Haghani I, Shokohi T, Hedayati MT, Aghili SR, Jedi A, Dadashi S, Shabanzadeh S, Hosseini T, Aslani N, Meis JF, Badali H. 2018. Low *in vitro* antifungal activity of tavaborole against yeasts and molds from onychomycosis. *Antimicrob Agents Chemother* 62:e01632-18. <https://doi.org/10.1128/AAC.01632-18>.

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Hamid Badali, badali@yahoo.com.

collection of clinical fungi from onychomycosis cases have been published. Therefore, we used a panel of isolates of different species of dermatophytes, molds, and yeasts from patients with onychomycosis to evaluate the *in vitro* activity of this novel drug and four comparator agents, i.e., voriconazole, itraconazole, fluconazole, and terbinafine.

A total of 170 clinical nail isolates were included in this study. Fifty-one yeasts, consisting of *Candida parapsilosis* ($n = 27$), *Candida tropicalis* ($n = 10$), *Candida albicans* ($n = 7$), *Candida krusei* ($n = 4$), *Candida orthopsilosis* ($n = 2$), *Candida guilliermondii* ($n = 1$), and *Candida glabrata* ($n = 1$); as well as 88 molds, including *Aspergillus flavus* ($n = 36$), *Aspergillus terreus* ($n = 21$), *Aspergillus niger* ($n = 17$), *Aspergillus tubingensis* ($n = 8$), *Fusarium proliferatum* ($n = 8$), *Trichophyton interdigitale* ($n = 8$), *Trichophyton rubrum* ($n = 5$), *Aspergillus oryzae* ($n = 3$), *Aspergillus fumigatus* ($n = 2$), *Fusarium solani* ($n = 2$), *Fusarium verticillioides* ($n = 2$), *Fusarium* sp. ($n = 2$), *Aspergillus uvarum* ($n = 1$), and *Trichophyton tonsurans* ($n = 1$), were recovered from patients suffering from fingernail ($n = 70$) and toenail ($n = 100$) infections. Isolates were cultured on Sabouraud dextrose agar (Difco) supplemented with chloramphenicol for 2 to 7 days at 30°C and identified to the species level by PCR restriction fragment length polymorphism and DNA sequencing as previously described (23–25, 33–36). *In vitro* antifungal susceptibility testing for filamentous fungi and yeast were performed according to Clinical and Laboratory Standards Institute (CLSI) documents M38-A2 and M27-A3, respectively (26, 27). Concentration ranges used were 0.016 to 16 µg/ml for tavaborole (Sigma-Aldrich, Germany), itraconazole (Janssen Research Foundation, Beerse, Belgium), and voriconazole (Pfizer, Central Research, Sandwich, United Kingdom); 0.004 to 4 µg/ml for terbinafine (Novartis Research Institute, Vienna, Austria); and 0.063 to 64 µg/ml for fluconazole (Pfizer). The maximal final concentration of dimethyl sulfoxide in the test wells was <1%. Trays were stored at –80°C until the day of testing. Briefly, conidial suspensions of filamentous fungi were obtained by scraping the mature colonies on potato dextrose agar (Difco) with a moistened swab. The turbidity was measured spectrophotometrically at a wavelength of 530 nm. Transmission was adjusted to 65% to 70% for dermatophytes, 80% to 82% for *Aspergillus* spp., and 69% to 70% for *Fusarium* isolates. To obtain the final inoculum, suspensions were diluted 1:50 in RPMI 1640 medium. Microdilution plates were incubated at 35°C for 48 h for *Aspergillus* and *Fusarium*, but trays were incubated at 35°C for 96 h for *Trichophyton*. MIC endpoints were defined as the lowest concentration that caused complete inhibition of growth. In contrast, yeast suspensions were adjusted spectrophotometrically at a wavelength of 530 nm to a transmission in the 75% to 77% range and diluted in RPMI 1640 medium to yield final inocula of 0.5 to 5×10^3 cells/ml. The microdilution trays were incubated at 35°C for 24 h. The MIC values were determined visually and were defined as the lowest concentration of drug that caused $\geq 50\%$ growth inhibition for all drugs. *C. krusei* (ATCC 6258) and *Paecilomyces variotii* (ATCC 3630) were used as quality controls. All tests were performed in duplicate, and differences of the mean values were determined by Student's *t* test with the statistical SPSS package (version 7.0). *P* values of <0.05 were considered statistically significant.

Table 1 summarizes the *in vitro* susceptibility pattern of 170 clinical nail isolates as the MIC range, MIC mode, MIC₅₀, and, when appropriate, the MIC₉₀ for the five tested antifungal drugs. Tavaborole demonstrated consistently very high MIC values against all filamentous fungi and yeast isolates, compared to those of the other antifungal drugs. Tavaborole showed high MICs for most of the *Candida* isolates (MIC₅₀ and MIC₉₀, 16 µg/ml), whereas the MIC₉₀s of voriconazole, itraconazole, and terbinafine were lowest for this genus, at 0.25, 4, and 4 µg/ml, respectively (Table 1). Unlike the study by Mao et al. (22), which reported MICs ranging from 0.5 to 1 µg/ml for *Candida* spp. and 0.125 to 4 µg/ml for the other yeasts, this study showed lower activity, with MIC ranges of 2 to 16 µg/ml. For *Aspergillus* strains, all antifungal agents except fluconazole demonstrated better activity than tavaborole. As presented in Table 1, MIC₅₀ values of fluconazole and tavaborole were 64 and 2 µg/ml, respectively, whereas all *Aspergillus* strains showed MIC₅₀ values of ≤ 1 µg/ml for the remaining drugs. The MICs for

TABLE 1 *In vitro* susceptibilities of five antifungal drugs against different fungal isolates from patients with onychomycosis^a

Genus	Species (no. of isolates)	MIC parameter	MIC (μg/ml) for:				
			Tavaborole	Voriconazole	Itraconazole	Fluconazole	Terbinafine
<i>Candida</i>	<i>C. parapsilosis</i> (27)	Range	2 to >16	0.008 to >16	0.125 to >16	0.0625 to >64	4 to >4
		MIC ₅₀	16	0.016	1	0.5	4
		MIC ₉₀	16	0.25	2	8	4
		GM	14.49	0.06	2.46	1.71	4
	<i>C. tropicalis</i> (10)	Range	8 to >16	0.0625 to >0.5	1 to >8	0.25 to >64	4 to >4
		MIC ₅₀	16	0.032	2	2	4
		MIC ₉₀	16	0.25	4	16	4
		GM	14.49	0.06	2.46	1.71	4
	<i>C. albicans</i> (7)	Range	4 to >16	0.008 to >0.016	0.25 to 16	0.125 to >4	4 to >4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>C. krusei</i> (4)	Range	8 to 16	0.0625 to 0.016	0.5 to 1	0.5 to 16	4 to >4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>C. orthopsilosis</i> (2)	Range	16	0.016	1	0.25 to 1	4 to >4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>C. guilliermondii</i> (1)	Range	16	0.125	4	4	>4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>C. glabrata</i> (1)	Range	16	0.125	4	2	>4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	All <i>Candida</i> strains (52)	Range	2 to >16	0.008 to >16	0.125 to >16	0.0625 to >16	4 to >4
MIC ₅₀		16	0.032	1	1	4	
MIC ₉₀		16	0.25	4	8	4	
GM		12.58	0.03	0.77	0.74	4	
<i>Aspergillus</i>	<i>A. flavus</i> (36)	Range	0.5 to 16	0.0625 to 0.5	0.0625 to 1	16 to >64	0.032 to 8
		MIC ₅₀	2	0.25	0.125	64	0.5
		MIC ₉₀	4	0.5	0.25	64	4
		GM	1.8	0.21	0.13	45.25	0.59
	<i>A. terreus</i> (21)	Range	1 to 4	0.125 to 1	0.0625 to 0.25	64	0.032 to 8
		MIC ₅₀	2	0.25	0.016	64	4
		MIC ₉₀	4	1	0.125	64	8
		GM	2.4	0.33	0.03	64	1.8
	<i>A. niger</i> (17)	Range	0.5 to 16	0.0625 to 2	0.0625 to >16	32 to >64	0.125 to 8
		MIC ₅₀	1	0.25	0.032	32	0.5
		MIC ₉₀	16	0.5	1	64	4
		GM	1.92	0.25	0.2	42.25	0.81
	<i>A. tubingensis</i> (8)	Range	1 to 8	0.125 to 1	0.25 to 1	64	0.25 to 8
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>A. oryzae</i> (3)	Range	1 to 8	0.0625 to 0.125	0.032 to 0.125	32 to 64	0.0625 to 1
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>A. fumigatus</i> (2)	Range	2 to 16	0.0625 to 0.25	0.0625 to 0.5	64 to >64	4 to >4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>A. uvarum</i> (1)	Range	0.5	0.125	0.016	>64	4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	All <i>Aspergillus</i> strains (88)	Range	0.5 to 16	0.0625 to 2	0.016 to >16	0.5 to >64	0.032 to >4
		MIC ₅₀	2	0.25	0.125	64	1

(Continued on next page)

Downloaded from <http://aac.asm.org/> on February 26, 2021 by guest

TABLE 1 (Continued)

Genus	Species (no. of isolates)	MIC parameter	MIC ($\mu\text{g/ml}$) for:				
			Tavaborole	Voriconazole	Itraconazole	Fluconazole	Terbinafine
		MIC ₉₀	4	0.5	0.5	64	4
		GM	2	0.24	0.1	50.79	0.92
Dermatophytes	<i>T. interdigitale</i> (8)	Range	4 to 16	0.016 to 0.0625	0.0625 to 0.125	16 to 32	0.008 to 4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>T. rubrum</i> (5)	Range	8 to 16	0.016 to >16	0.016 to >16	2 to 16	0.008 to >4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>T. tonsurans</i> (1)	Range	8	0.032	0.032	16	0.004
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	All dermatophyte strains (14)	Range	4 to 16	0.016 to >16	0.016 to >16	2 to 32	0.004 to >4
		MIC ₅₀	8	0.032	0.0625	16	0.004
MIC ₉₀		16	0.032	0.0625	32	0.008	
GM		9.28	0.02	0.03	10.24	0.007	
<i>Fusarium</i>	<i>F. proliferatum</i> (8)	Range	16 to >16	1 to 4	>16	64 to >64	>4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>F. verticillioides</i> (2)	Range	8-16	1->16	8->16	>64	0.032- >4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>F. solani</i> (2)	Range	16 to >16	0.5 to 2	>16	>64	>4
		MIC ₅₀	ND	ND	ND	ND	ND
		MIC ₉₀	ND	ND	ND	ND	ND
		GM	ND	ND	ND	ND	ND
	<i>Fusarium</i> sp. (2)	Range	16	2	>16	>64	>4
		MIC ₅₀	ND	ND	ND	ND	ND
MIC ₉₀		ND	ND	ND	ND	ND	
GM		ND	ND	ND	ND	ND	
All <i>Fusarium</i> strains (14)	Range	8 to >16	0.5 to >16	8 to >16	64 to >64	0.032 to >4	
	MIC ₅₀	16	2	8	64	4	
	MIC ₉₀	16	4	8	64	4	
	GM	14.67	2	8	64	4	

^aGM, geometric mean; MIC₅₀, concentration at which 50% of the isolates were inhibited; MIC₉₀, concentration at which 90% of the isolates were inhibited; ND, not determined.

tavaborole against all dermatophyte isolates ranged from 4 to 16 $\mu\text{g/ml}$, compared to 0.016 to >16 $\mu\text{g/ml}$ for voriconazole, 0.016 to >16 $\mu\text{g/ml}$ for itraconazole, 2 to 32 $\mu\text{g/ml}$ for fluconazole, and 0.004 to >4 $\mu\text{g/ml}$ for terbinafine. Overall, MIC₅₀ and MIC₉₀ values of tavaborole (8 and 16 $\mu\text{g/ml}$) had low activities compared to those of itraconazole (both 0.0625 $\mu\text{g/ml}$) and terbinafine (0.004 and 0.008 $\mu\text{g/ml}$) used for treatment of onychomycosis due to dermatophytes. Remarkably, *Fusarium* sp. demonstrated extremely high MICs to tavaborole (8 to >16 $\mu\text{g/ml}$); however, the lowest MIC ranges were found with terbinafine (0.032 to >4 $\mu\text{g/ml}$). Tavaborole MIC₅₀ and MIC₉₀ values of all isolates were 4 and 16 $\mu\text{g/ml}$, respectively, whereas those of the other agents were, respectively, 0.125 and 1 $\mu\text{g/ml}$ for voriconazole, 0.25 and 2 $\mu\text{g/ml}$ for itraconazole, 4 and 64 $\mu\text{g/ml}$ for fluconazole, and 2 and 4 $\mu\text{g/ml}$ for terbinafine. Furthermore, MIC₉₀ values of tavaborole against all isolates were 2 and 3 log₂ dilutions higher than terbinafine and itraconazole, respectively. Tavaborole inhibited only 14.7% ($n = 25$) of all isolates at a concentration of ≤ 1 $\mu\text{g/ml}$, whereas itraconazole and terbinafine inhibited 78.82% ($n = 134$) and 40% ($n = 69$) of isolates with this MIC value, respectively. Mao et al. (22) examined tavaborole MIC values (0.5 $\mu\text{g/ml}$) for only 1 isolate of *A. fumigatus*. Among 88 *Aspergillus* strains in the current study, just 5 isolates,

TABLE 2 *In vitro* susceptibilities of 5 antifungal drugs against 170 fungal isolates from different patients with onychomycosis^b

Antifungal drug	MIC ($\mu\text{g/ml}$) ^a														MIC range	MIC ₅₀	MIC ₉₀	GM	
	0.004	0.008	0.016	0.031	0.063	0.125	0.25	0.5	1	2	4	8	16	>64					
Tavaborole								5	20	45	18	19	63		0.5 to 16	4	16	4.44	
Voriconazole		4	27	14	16	30	30	25	8	9	4		3		0.008 to >16	0.125	1	0.13	
Itraconazole			19	10	18	23	20	20	24	7	8	2	19		0.016 to >16	0.25	2	0.2	
Fluconazole					1	7	5	11	7	10	5	2	12	8	102	0.0625 to >64	4	64	3.67
Terbinafine	10	9	3	1	12	10	13	11	11	89	1				0.004 to >4	2	4	0.74	

^aNumbers in boldface are modal values.

^bGM, geometric mean; MIC₅₀, concentration at which 50% of the isolates were inhibited; MIC₉₀, concentration at which 90% of the isolates were inhibited.

including 2 *A. flavus*, 2 *A. niger*, and 1 *A. uvarum*, were inhibited at an MIC of 0.5 $\mu\text{g/ml}$, and 28.4% ($n = 25$) of all isolates were inhibited at $\leq 1 \mu\text{g/ml}$ of tavaborole (Tables 1 and 2).

Tavaborole, in contrast to other recently FDA-approved topical antifungal agents for onychomycosis, including efinaconazole (28) and luliconazole (29), demonstrated lower activity against *Aspergillus* spp. Luliconazole showed excellent activity against susceptible and resistant *A. fumigatus* isolates, with MIC ranges of <0.001 to 0.016 $\mu\text{g/ml}$ (30). Also, Siu et al. (14) found that efinaconazole had geometric mean MICs of 0.089 $\mu\text{g/ml}$ for *A. fumigatus* and 0.11 $\mu\text{g/ml}$ for *A. flavus* from onychomycosis.

MICs of tavaborole for dermatophyte isolates were similar to those reported by Mao et al. (22) but different from the those in the FDA study. MIC ranges in our study were 4 to 16 $\mu\text{g/ml}$, Mao et al. (22) reported MICs of 1 to 8 $\mu\text{g/ml}$, and the FDA evaluation demonstrated MIC ranges of 0.5 to 2 $\mu\text{g/ml}$. Based on the MIC₉₀ value (16 $\mu\text{g/ml}$), tavaborole showed low activity, which was not comparable to the MIC₉₀ of terbinafine (0.008 $\mu\text{g/ml}$) and itraconazole with (0.0625 $\mu\text{g/ml}$). Almost all dermatophyte isolates (92%) were inhibited at $\geq 8 \mu\text{g/ml}$ of tavaborole, except for a single isolate with an MIC of 4 $\mu\text{g/ml}$ (Table 1). Finally, tavaborole MICs of *Fusarium* isolates in this study (8 to 16 $\mu\text{g/ml}$) were higher than those found in other reports ($<0.5 \mu\text{g/ml}$) (22). With the exception of a single isolate of *F. verticillioides* which had an MIC of 8 $\mu\text{g/ml}$, all had MICs of 16 $\mu\text{g/ml}$ (Table 1). These results concur with previously published data on azoles versus *Fusarium* sp., with MICs of ≥ 8 for itraconazole (31, 32). In conclusion, we found that the *in vitro* antifungal activity of tavaborole against a panel of different agents of onychomycosis is inferior to those of terbinafine and azoles, except for fluconazole.

ACKNOWLEDGMENTS

The work of M.A. was supported by Mazandaran University of Medical Sciences, Sari, Iran (grant no. 2812), which we gratefully acknowledge. J.F.M. received grants from Astellas, Basilea, and Merck. He has been a consultant to Astellas, Basilea, Scynexis, and Merck and received speaker's fees from Merck, United Medical, TEVA, and Gilead Sciences.

We have no other conflicts of interest to declare.

We alone are responsible for the content and writing of the paper.

REFERENCES

- Faergemann J, Baran R. 2003. Epidemiology, clinical presentation and diagnosis of onychomycosis. *Br J Dermatol* 149:1–4. <https://doi.org/10.1046/j.1365-2133.149.s65.4.x>.
- Papini M, Piraccini BM, Difonzo E, Brunoro A. 2015. Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification. *Mycoses* 58:659–664. <https://doi.org/10.1111/myc.12396>.
- Svejgaard EL, Nilsson J. 2004. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. *Mycoses* 47:131–135. <https://doi.org/10.1111/j.1439-0507.2004.00968.x>.
- Foster KW, Ghannoum MA, Elewski BE. 2004. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. *J Am Acad Dermatol* 50:748–752. [https://doi.org/10.1016/S0190-9622\(03\)02117-0](https://doi.org/10.1016/S0190-9622(03)02117-0).
- Zarei F, Mirhendi H, Fakhim H, Geramishoar M. 2015. The first case of onychomycosis due to *Aspergillus uvarum* (section Nigri). *Mycoses* 58:239–242. <https://doi.org/10.1111/myc.12304>.
- Sigurgeirsson B, Baran R. 2014. The prevalence of onychomycosis in the global population: a literature study. *J Eur Acad Dermatol Venereol* 28:1480–1491. <https://doi.org/10.1111/jdv.12323>.
- Falahati M, Ghoghji A, Abastabar M, Ghasemi Z, Farahyar S, Roudbary M, Hedayati MT, Armaki MT, Hoseinnejad A. 2016. The first case of total dystrophic onychomycosis caused by *Aspergillus clavatus* resistant to

- antifungal drugs. *Mycopathologia* 181:273–277. <https://doi.org/10.1007/s11046-015-9954-6>.
8. Westerberg DP, Voyack MJ. 2013. Onychomycosis: current trends in diagnosis and treatment. *Am Fam Physician* 88:762–770.
 9. Ghannoum M, Isham N. 2014. Fungal nail infections (onychomycosis): a never-ending story? *PLoS Pathog* 10:e1004105. <https://doi.org/10.1371/journal.ppat.1004105>.
 10. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. 2005. Epidemiology and clinical classification of onychomycosis. *J Eur Acad Dermatol Venereol* 19:8–12. <https://doi.org/10.1111/j.1468-3083.2005.01281.x>.
 11. Gupta AK, Versteeg SG, Shear NH. 2017. Onychomycosis in the 21st Century: an update on diagnosis, epidemiology, and treatment. *J Cutan Med Surg* 21:525–539. <https://doi.org/10.1177/1203475417716362>.
 12. Jones T, Tavakkol A. 2013. Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis. *Antimicrob Agents Chemother* 57:2684–2689. <https://doi.org/10.1128/AAC.02370-12>.
 13. Baghi N, Shokohi T, Badali H, Makimura K, Rezaei-Matehkolaei A, Abdollahi M, Didehdar M, Haghani I, Abastabar M. 2016. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. *Med Myco* 54:757–763. <https://doi.org/10.1093/mmy/myw016>.
 14. Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, Fothergill A. 2013. Comparison of *in vitro* antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. *Antimicrob Agents Chemother* 57:1610–1616. <https://doi.org/10.1128/AAC.02056-12>.
 15. Tabata Y, Takei-Masuda N, Kubota N, Takahata S, Ohyama M, Kaneda K, Iida M, Maebashi K. 2016. Characterization of antifungal activity and nail penetration of ME1111, a new antifungal agent for topical treatment of onychomycosis. *Antimicrob Agents Chemother* 60:1035–1039. <https://doi.org/10.1128/AAC.01739-15>.
 16. Gupta AK, Versteeg SG. 2016. Tavaborole – a treatment for onychomycosis of the toenails. *Expert Rev Clin Pharmacol* 9:1145–1152. <https://doi.org/10.1080/17512433.2016.1206467>.
 17. Gupta AK, Daigle D. 2014. Potential role of tavaborole for the treatment of onychomycosis. *Future Microbiol* 9:1243–1250. <https://doi.org/10.2217/fmb.14.76>.
 18. Seiradake E, Mao W, Hernandez V, Baker SJ, Plattner JJ, Alley MR, Cusack S. 2009. Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. *J Mol Biol* 390:196–207. <https://doi.org/10.1016/j.jmb.2009.04.073>.
 19. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H, Zhang Y-K, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MR. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. *Science* 316:1759–1761. <https://doi.org/10.1126/science.1142189>.
 20. Murdan S. 2002. Drug delivery to the nail following topical application. *Int J Pharm* 236:1–26. [https://doi.org/10.1016/S0378-5173\(01\)00989-9](https://doi.org/10.1016/S0378-5173(01)00989-9).
 21. Coronado D, Merchant T, Chanda S, Zane LT. 2015. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical. *J Drugs Dermatol* 14:609–614.
 22. Mao W, Rock FL, Alley MR. 2006. AN2690, a topical antifungal agent in development for the treatment of onychomycosis represents a new class and has a novel mechanism of action. http://www.anacor.com/pdf/SID_P769.pdf. Accessed 8 March 2016.
 23. Abastabar M, Mirhendi H, Rezaei-Matehkolaei A, Shidfar MR, Kordbacheh P, Makimura K. 2014. Restriction analysis of β -tubulin gene for differentiation of the common pathogenic dermatophytes. *J Clin Lab Anal* 28:91–96. <https://doi.org/10.1002/jcla.21649>.
 24. Nasri T, Hedayati MT, Abastabar M, Pasqualotto AC, Armaki MT, Hoseinejad A, Nabili M. 2015. PCR-RFLP on β -tubulin gene for rapid identification of the most clinically important species of *Aspergillus*. *J Microbiol Methods* 117:144–147. <https://doi.org/10.1016/j.jmimet.2015.08.007>.
 25. Fesharaki SH, Haghani I, Mousavi B, Kargar ML, Boroumand M, Anvari MS, Abbasi K, Meis JF, Badali H. 2013. Endocarditis due to a co-infection of *Candida albicans* and *Candida tropicalis* in a drug abuser. *J Med Microbiol* 62:1763–1767. <https://doi.org/10.1099/jmm.0.060954-0>.
 26. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
 27. Clinical and Laboratory Standards Institute. 2018. Reference method for broth dilution antifungal susceptibility testing of yeasts—4th ed. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
 28. Lipner SR, Scher RK. 2015. Efinaconazole in the treatment of onychomycosis. *Infect Drug Resist* 8:163–172. <https://doi.org/10.2147/IDR.S69596>.
 29. Khanna D, Bharti S. 2014. Luliconazole for the treatment of fungal infections: an evidence-based review. *Core Evid* 9:113–124. <https://doi.org/10.2147/CE.S49629>.
 30. Abastabar M, Rahimi N, Meis JF, Aslani N, Khodavaisy S, Nabili M, Rezaei-Matehkolaei A, Makimura K, Badali H. 2016. Potent activities of novel imidazoles lanoconazole and luliconazole against a collection of azole resistant and susceptible *Aspergillus fumigatus* strains. *Antimicrob Agents Chemother* 60:6916–6919. <https://doi.org/10.1128/AAC.01193-16>.
 31. Abastabar M, Al-Hatmi AMS, Vafaei Moghaddam M, de Hoog GS, Haghani I, Aghili SR, Shokohi T, Hedayati MT, Daie Ghazvini R, Kachuei R, Rezaei-Matehkolaei A, Makimura K, Meis JF, Badali H. 2018. Potent activities of luliconazole, lanoconazole, and eight comparators against molecularly characterized *Fusarium* species. *Antimicrob Agents Chemother* 62:e00009-18. <https://doi.org/10.1128/AAC.00009-18>.
 32. Al-Hatmi AM, Meis JF, de Hoog GS. 2016. *Fusarium*: molecular diversity and intrinsic drug resistance. *PLoS Pathog* 12:e1005464. <https://doi.org/10.1371/journal.ppat.1005464>.
 33. Badali H, Fakhim H, Zarei F, Nabili M, Vaezi A, Poorzad N, Dolatabadi S, Mirhendi H. 2016. *In vitro* activities of five antifungal drugs against opportunistic agents of *Aspergillus Nigri* complex. *Mycopathologia* 181: 235–240. <https://doi.org/10.1007/s11046-015-9968-0>.
 34. Vaezi A, Fakhim H, Arastehfar A, Shokohi T, Hedayati MT, Khodavaisy S, Rezaei-Matehkolaei A, Badiie P, Hagen F, Lass-Flörl C, Dannaoui E, Meis JF, Badali H. 2018. *In vitro* antifungal activity of amphotericin B and 11 comparators against *Aspergillus terreus* species complex. *Mycoses* 61: 134–142. <https://doi.org/10.1111/myc.12716>.
 35. Fakhim H, Vaezi A, Dannaoui E, Sharma C, Mousavi B, Chowdhary A, Meis JF, Badali H. 2018. *In vitro* combination of voriconazole with micafungin against azole-resistant clinical isolates of *Aspergillus fumigatus* from different geographical regions. *Diagn Microbiol Infect Dis* 91:266–268. <https://doi.org/10.1016/j.diagmicrobio.2018.03.003>.
 36. Diba K, Makhdoomi K, Nasri E, Vaezi A, Javidnia J, Gharabagh DJ, Jazani NH, Reza Chawshin A, Badiie P, Badali H, Fakhim H. 2018. Emerging *Candida* species isolated from renal transplant recipients: species distribution and susceptibility profiles. *Microb Pathog* 125:240–245. <https://doi.org/10.1016/j.micpath.2018.09.026>.